Sign up to save your podcasts
Or
Share Commercial Success Beyond Regulatory Clearance w. Robert Hamilton
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Commercial Success Beyond Regulatory Clearance w. Robert Hamilton
FDA clearance used to feel like the finish line. Robert Hamilton thought so too when he founded NeuraSignal. Then he learned the hard way that regulatory approval is just the beginning. In this episode, Robert shares the journey from developing the world's first fully automated robotic system for cerebral blood flow monitoring to building a commercially successful medtech company with operations in both the US and Canada. You'll hear about the pivot from traumatic brain injury to ischemic stroke when reimbursement pathways didn't align, why expanding internationally too early cost hundreds of thousands of dollars, and how clinical trial site selection can make or break your timeline and budget. Robert breaks down the three-legged stool every founder needs (regulatory, clinical, reimbursement), why usability testing is not a checkbox exercise, and how quality management systems evolve from compliance tools into competitive advantages. If you think getting through the FDA is the hard part, this conversation will recalibrate your expectations and strategy.
Timestamps:
00:00 - Introduction: From UCLA ICU to commercializing breakthrough technology
03:00 - The accidental discovery that became Neuros Signal
05:00 - The three-legged stool: Regulatory, clinical, and reimbursement strategy
08:00 - Three company name changes: Lessons in trademarks and branding
10:00 - Why cerebral blood flow monitoring matters and the gap in the market
13:00 - Three times higher diagnostic rates: Real clinical impact stories
16:00 - When FDA clearance felt like the end (but was actually the beginning)
19:00 - Usability testing beyond regulatory checkboxes
22:00 - Fundraising realities: Structure matters as much as valuation
25:00 - The strategic approach to multiple 510(k) submissions
28:00 - Quality management systems: From compliance burden to competitive advantage
33:00 - Most expensive mistakes: International expansion and clinical trial site selection
36:00 - Why reimbursement work takes most of your time post-clearance
39:00 - Rapid fire: Post-FDA advice, regulatory strategy mistakes, resources
Follow Melita and Robert:
Connect with Melita:
LinkedIn: https://www.linkedin.com/in/melitaball/
Website: https://www.mbcaconsulting.com/
Connect with Robert:
LinkedIn: https://www.linkedin.com/in/hamiltonrobert/
Website: https://neurasignal.com/
View all episodes
By Melita BallFDA clearance used to feel like the finish line. Robert Hamilton thought so too when he founded NeuraSignal. Then he learned the hard way that regulatory approval is just the beginning. In this episode, Robert shares the journey from developing the world's first fully automated robotic system for cerebral blood flow monitoring to building a commercially successful medtech company with operations in both the US and Canada. You'll hear about the pivot from traumatic brain injury to ischemic stroke when reimbursement pathways didn't align, why expanding internationally too early cost hundreds of thousands of dollars, and how clinical trial site selection can make or break your timeline and budget. Robert breaks down the three-legged stool every founder needs (regulatory, clinical, reimbursement), why usability testing is not a checkbox exercise, and how quality management systems evolve from compliance tools into competitive advantages. If you think getting through the FDA is the hard part, this conversation will recalibrate your expectations and strategy.
Timestamps:
00:00 - Introduction: From UCLA ICU to commercializing breakthrough technology
03:00 - The accidental discovery that became Neuros Signal
05:00 - The three-legged stool: Regulatory, clinical, and reimbursement strategy
08:00 - Three company name changes: Lessons in trademarks and branding
10:00 - Why cerebral blood flow monitoring matters and the gap in the market
13:00 - Three times higher diagnostic rates: Real clinical impact stories
16:00 - When FDA clearance felt like the end (but was actually the beginning)
19:00 - Usability testing beyond regulatory checkboxes
22:00 - Fundraising realities: Structure matters as much as valuation
25:00 - The strategic approach to multiple 510(k) submissions
28:00 - Quality management systems: From compliance burden to competitive advantage
33:00 - Most expensive mistakes: International expansion and clinical trial site selection
36:00 - Why reimbursement work takes most of your time post-clearance
39:00 - Rapid fire: Post-FDA advice, regulatory strategy mistakes, resources
Follow Melita and Robert:
Connect with Melita:
LinkedIn: https://www.linkedin.com/in/melitaball/
Website: https://www.mbcaconsulting.com/
Connect with Robert:
LinkedIn: https://www.linkedin.com/in/hamiltonrobert/
Website: https://neurasignal.com/